咋了？农药巨头正在考虑，把自己卖了！

Core Viewpoint - FMC Corporation is exploring various strategic options, including the potential sale of the company, due to significant financial challenges and declining revenues [1][2] Financial Performance - FMC reported a revenue of $3.47 billion for 2025, a decrease of 18% compared to 2024, primarily due to a 6% drop in product prices [1] - The company experienced a net loss of $2.24 billion for the year, which is a reduction of $2.58 billion from the previous year [1] - For 2026, FMC expects revenues to be between $3.6 billion and $3.8 billion, reflecting a 5% decline from the previous year [2] - Adjusted EBITDA is projected to be between $670 million and $730 million, a 17% decrease year-over-year [2] Strategic Challenges - The expiration of the patent for the insecticide Rynaxypyr has posed strategic and operational challenges for FMC [1] - The company is facing ongoing debt issues, with a plan to repay $1 billion through asset sales and licensing agreements [1] - Standard & Poor's downgraded FMC's credit rating from BBB- to BB+, indicating a non-investment grade status, due to anticipated competitive pressures from generic products, particularly in Latin America and Asia [2] Business Outlook - FMC's chairman and CEO, Pierre Brondeau, emphasized the focus on implementing operational plans to strengthen the balance sheet and enhance overall business competitiveness by 2026 [2] - The company is optimistic about its four new active ingredients and believes that increased investment in these technologies could significantly enhance shareholder value [1]